Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2012 - 2026)

Biocryst Pharmaceuticals' Cost of Revenue history runs 15 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• Quarterly Cost of Revenue rose 17.71% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 27.69% YoY) and the FY2025 annual result came in at $19.1 million, up 55.47% from the prior year.
• Cost of Revenue was $5.4 million for Q1 2026 at Biocryst Pharmaceuticals, down from $9.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $9.5 million in Q4 2025 and bottomed at $236000.0 in Q1 2022.
• A 5-year average of $2.8 million and a median of $2.2 million in 2025 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 499.49% in 2022, while the deepest fall reached 96.02% in 2022.
• Biocryst Pharmaceuticals' Cost of Revenue stood at $2.4 million in 2022, then tumbled by 34.66% to $1.6 million in 2023, then surged by 291.39% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025, then sank by 43.53% to $5.4 million in 2026.
• Business Quant data shows BCRX's Cost of Revenue at $5.4 million in Q1 2026, $9.5 million in Q4 2025, and $2.2 million in Q3 2025.